Over the past 2 decades, multiple studies have clearly demonstrated that eradication of hepatitis C virus (HCV; ie, sustained virologic response [SVR]) with interferon (IFN)-based treatment is associated with a significant decrease in the risk of the development of hepatocellular carcinoma (HCC) in people with compensated liver disease; however, this risk is not eliminated.1 In the new era of IFN-free direct acting antiviral (DAA)-based therapy, successful treatment might similarly be expected to result in reductions in the incidence of de novo HCC.